Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Electronic address: Ingrid.pabinger@meduniwien.ac.at.
Ingrid
I
Pabinger-Fasching
Hemophilia Comprehensive Care Center and Hematology Department, Louis Pradel University Hospital, Lyon, France. Electronic address: claude.negrier@chu-lyon.fr.
Claude
C
Négrier
D002986:Clinical Trials as Topic; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D015942:Factor VIIa / Q000627:therapeutic use*; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa